Search Images Maps Play YouTube News Gmail Drive More »
Sign in
Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader.

Patents

  1. Advanced Patent Search
Publication numberUSRE33239 E
Publication typeGrant
Application numberUS 07/350,891
Publication dateJun 26, 1990
Filing dateMay 12, 1989
Priority dateSep 6, 1983
Fee statusPaid
Publication number07350891, 350891, US RE33239 E, US RE33239E, US-E-RE33239, USRE33239 E, USRE33239E
InventorsSoren Halskov
Original AssigneeFarmaceutisk Laboratorium Ferring A/S
Export CitationBiBTeX, EndNote, RefMan
External Links: USPTO, USPTO Assignment, Espacenet
Packaged stable enema solution or suspension containing 5-aminosalicyclic acid
US RE33239 E
Abstract
A packaged enema solution or suspension consisting essentially of an effective amount of 5-ASA or a pharmaceutically acceptable salt or ester thereof, a chelating agent, in antioxidant and a buffer, the solution or suspension having a pH value of from 4 to 7 and being contained in a plastic bottle under an inert gas, the plastic bottle being packaged in a diffusion-tight light-impervious package in the same inert gas as is present in the bottle.
Images(1)
Previous page
Next page
Claims(15)
What is claimed is:
1. A packaged enema solution or suspension consisting essentially of an effective amount of 5-ASA or a pharmaceutically acceptable salt or ester thereof, a chelating agent, an antioxidant and a buffer, said solution or suspension having a pH value of about 4.8 and being contained in a plastic bottle under an inert gas, said plastic bottle being packaged in a diffusion-tight light-impervious package in the same inert gas as is present in the bottle.
2. A packaged enema solution or suspension according to claim 1, wherein the chelating agent comprises EDTA, the antioxidant comprises sodium pyrosulfite and the buffer comprises citric acid and sodium hydroxide. .[.3. A packaged enema solution or suspension according to claim 1,
wherein the buffer is sodium bicarbonate and hydrochloric acid..]. 4. An enema solution or suspension according to claim 1, wherein the .[.5-aminosalicyclic.]. .Iadd.5-aminosalicylic .Iaddend.acid is sufficiently pure to avoid autooxidation, having no additional HPLC
fluospectrophotometric and spectrophotometric peaks. 5. A packaged enema solution or suspension according to claim 1, wherein the inert gas is
argon, nitrogen or carbon dioxide. 6. A packaged enema solution or suspension according to claim 1 consisting essentially of substantially pure .[.5-aminosalicyclic.]. .Iadd.5-aminosalicylic .Iaddend.acid or a pharmaceutically acceptable salt or ester thereof, ethylenediaminetetraacetic acid, sodium pyrosulfite, citric acid, sodium
hydroxide and purified water. 7. A packaged enema solution or suspension
according to claim 1, wherein the plastic bottle is polyethylene. 8. A packaged enema solution or suspension according to claim 7, wherein a polyethylene granulate used for producing the polyethylene bottle is deoxidized by alternately evacuating the granulate and flooding the
granulate with nitrogen gas. 9. A package enema solution or suspension according to claim 8, wherein the deoxidized granulate is extruded, formed into a bottle by means of an inert gas, and the bottle is filled with said
enema solution. 10. A package enema solution or suspension according to claim 9, the filled bottle is conveyed directly to a packing chamber wherein the bottle is packed into an aroma-tight bag under an inert gas,
said bag being sealed by welding before being contacted with air. 11. A packaged enema solution or suspension according to claim 10, wherein the
aroma-tight bag is a plastic aluminum laminate. 12. A packaged enema solution or suspension according to claim 11, containing per 100 ml of solution about 0.2 to 4.0 g .[.5-aminosalicyclic.]. .Iadd.5-aminosalicylic .Iaddend.acid, about 50 mg to 200 mg of sodium pyrosulfite, about 0.5 to 1.5 g citric acid, about 0.5 to 2 g sodium hydroxide, about 5 to 30 mg
sodium EDTA, and purified water. 13. A packaged enema solution or suspension according to claim 12, containing per 100 ml of solution about 1 g of .[.5-aminosalicyclic.]. .Iadd.5-aminosalicylic .Iaddend.acid, about 200 mg of sodium pyrosulfite, about 1 g citric acid, about 20 mg sodium EDTA, and sufficient sodium hydroxide and purified water to maintain said
pH of 4.8. .Iadd.14. A packaged enema solution or suspension consisting essentially of an effective amount of 5-ASA or a pharmaceutically acceptable salt or ester thereof, a chelating agent, an antioxidant and a buffer, said solution or suspension having a pH value of from 4 to 5 and being contained in a plastic bottle under an inert gas, said plastic bottle being packaged in a diffusion-tight light-impervious package in the same inert gas as is present in the bottle. .Iaddend. .Iadd.15. A packaged enema solution or suspension according to claim 14, wherein the antioxidant is sodium or potassium pyrosulfite. .Iaddend. .Iadd.16. A packaged enema solution or suspension according to claim 15, wherein the pyrosulfite is potassium pyrosulfite. .Iaddend. .Iadd.17. A packaged enema solution or suspension according to claim 16, containing per 100 ml of solution or suspension about 50 mg to 200 mg of potassium pyrosulfite. .Iaddend. .Iadd.18. A packaged enema solution or suspension according to claim 17, wherein the chelating agent is ethylene diaminetetraacetic acid or one of its alkali metal salts. .Iaddend. .Iadd.19. A packaged enema solution or suspension according to claim 18, wherein the chelating agent is one of the alkali metal salts of ethylene diaminetetraacetic acid.
.Iaddend. .Iadd.20. A packaged enema solution or suspension according to claim 19, wherein the enema solution or suspension has a pH value of from 4.5 to 5. .Iaddend. .Iadd.21. A packaged enema solution or suspension according to claim 20, wherein the enema solution or suspension is a suspension. .Iaddend. .Iadd.22. A packaged enema solution or suspension consisting essentially of an effective amount of 5-ASA, an alkali metal salt of ethylene diaminetetraacetic acid, potassium pyrosulfite, and a buffer, said solution or suspension having a pH value of from 4 to 5 and being contained in a plastic bottle under an inert gas, said plastic bottle being packaged in a diffusion-tight light-impervious package in the same inert gas as is present in the bottle. .Iaddend. .Iadd.23. A packaged enema solution or suspension according to claim 22, wherein the enema solution or suspension has a pH value of from 4.5 to 5. .Iaddend. .Iadd.24. A packaged enema solution or suspension according to claim 22, wherein the enema solution or suspension has a pH value of about 4.8. .Iaddend. .Iadd.25. A packaged enema solution or suspension according to claim 22, containing per 100 ml of said solution or suspension about 50 mg
to 200 mg of potassium pyrosulfite. .Iaddend. .Iadd.26. A packaged enema solution or suspension according to claim 25, wherein the enema solution or suspension is a suspension. .Iaddend.
Description

This application is a continuation of application Ser. No. 529,769, filed Sept. 6, 1983, now abandoned.

BACKGROUND OF THE INVENTION

1. Field of the Invention

This invention concerns an enema solution or suspension which is suitable for rectal administration of 5-.[.aminosalicyclic.]..Iadd.aminosalicylic .Iaddend.acid (5-ASA) in mammals. The present enema solutions are useful in the treatment of bowel diseases, in particular, ulcerative colitis, Crohn's disease located in the colon and .[.proctoigmoiditis.]. .Iadd.proctosigmoiditis.Iaddend..

2. State of the Prior Art

.[.Salicyclazosulfapyridine.]. .Iadd.Salicylazosulfapyridine .Iaddend.(SASP) has for a long period of time been a cornerstone in the treatment of ulcerative colitis and has been used in various pharmaceutical dosage forms including enemas. When SASP reaches the colon, it is split by bacteria into sulfapyridine (SP) and 5-ASA and, as explained in detail in copending U.S. application Ser. No. 555,533, filed Nov. 28, 1983, which is a continuation application of Ser. No. 270,517, filed May 29, 1981, now abandoned, and based on International Application No. WO81/02671, both of which are incorporated by reference, most experts now hold the active moiety of SASP to be 5-ASA.

Azad Khan et al, Lancet, 1977, pp. 892-95, compared suspensions of SASP, SP and 5-ASA administered rectally and concluded that the therapeutic active moiety was 5-ASA and that SP only acts as a carrier to ensure that 5-ASA is not released until it has reached the colon. Stability tests showed that SASP and SP suspensions were stable at room temperature while the 5-ASA suspension showed some decay and had to be made up in fresh batches every three months and stored in a refrigerator until used.

Similar observations were made by Campieri et al, Lancet, Aug. 8, 1981, pp. 220-21, who carried out a comparison trial between 5-ASA and hydrocortisone. Since 5-ASA turned brown in solution, they added charcoal to the hydrocortisone as coloring agent in order to ensure double-blindness.

While enemas containing 5-ASA have thus proved useful in the treatment of ulcerative colitis, their limited stability is a major problem and a solution to this problem would be of great advantage.

It has now been discovered that the desired stability can be obtained by packaging an aqueous solution or suspension of 5-ASA or a pharmaceutically acceptable salt or ester thereof being contained in a plastic bottle under an inert gas in a diffusion-tight package impervious to light in the same inert gas as was used in the plastic bottle.

The 5-ASA solution or suspension should further contain a chelating agent, an antioxidant and a buffer in order to provide a pH value of from 4 to 7.

The presence of the same inert gas on both sides of the plastic bottle provides an equilibrium which effectively cooperates with the various stabilizers and the diffusion-tight light-impervious package and provides a stability of a year or more.

SUMMARY OF THE INVENTION

Hence, the invention concerns a packaged enema solution or suspension consisting essentially of an effective amount of 5-ASA or a pharmaceutically acceptable salt or ester thereof, a chelating agent, an antioxidant and a buffer, said solution or suspension having a pH value of from 4 to 7 and being contained in a plastic bottle under an inert gas, said plastic bottle being packaged in a diffusion-tight light-impervious package in the same inert gas as is present in the bottle.

BRIEF DESCRIPTION OF THE DRAWING

The invention will be further illustrated with reference to the accompanying single FIGURE of drawing which shows a partly torn away package containing a liquid-filled enema bottle.

The drawing shows a laminated foil package 1 enclosing an anema bottle 2 containing an enema solution or suspension 3.

The laminated foil package 1 is heat-sealed along each edge at 1a and along the bottom at 1b and the top at 1c, respectively.

Preferably, the package is formed from a heat-sealable plastic-metal laminate, e.g., a polyethylenealuminum laminate 4.

The bottle is constituted by a container part 6, an intermediate part 7 and a sealed closure part 8.

DETAILED DESCRIPTION OF THE INVENTION

The therapeutically active ingredient 5-ASA may be present in the form of the free acid or a pharmaceutically acceptable salt or ester thereof.

The salts of 5-ASA may be acid addition salts, in particular, the hydrochloride, but any pharmaceutically acceptable, non-toxic organic or inorganic acid may be used.

Also, salts formed with the carboxylic acid group may be used. As examples may be mentioned alkali metal salts (K, Na), alkaline earth metal salts (Ca, Mg), but again any pharmaceutically acceptable, non-toxic salt may be used. The Na- and Ca- salts are preferred.

In German Offenlegungsschrift No. 2,712,934, a number of esters of ortho-, meta- and .[.para-salicyclic.]. .Iadd.para-salicylic .Iaddend.acid are disclosed. Said esters are effective as ultraviolet ray screening compounds thereby rendering themselves useful in preventing solar burning. The disclosed meta- (or 5-).[.aminosalicyclic.]..Iadd.aminosalicylic .Iaddend.esters and a number of related esters are also applicable in the enema according to the invention.

Applicable esters are, e.g., straight chain or branched C1 -C18 alkyl esters such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, amyl, hexyl, heptyl, octyl, nonyl, decyl, lauryl, myristyl, cetyl, and stearyl, etc.; straight chain or branched C2 -C18 alkenyl esters, e.g., vinyl, allyl, undecenyl, oleyl, linolenyl, etc.; C3 -C8 cycloalkyl esters, e.g., cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl, etc.; aryl esters, e.g., phenyl, toluyl, xylyl, naphthyl, etc.; alicyclic esters, e.g., menthyl, etc.; or aralkyl esters, e.g., benzyl, phenethyl, etc.

Generaly speaking, the proper selection of the active ingredient depends on the selected type of formulation, the disease pattern, especially the site and type of the disease, and the desired release of the active ingredient, as shall be further expounded below together with the concept "effective amount".

The physical state and solubility characteristics of the 5-ASA derivatives must be taken into account when selecting a suitable carrier composition for the ingredient.

The preferred active ingredient at present is the free acid, 5-ASA.

Preferably, the 5-ASA is extremely pure in order to prevent autooxidation. The purity is manifested by the absence of additional high pressure liquid chromatography (HPLC) peaks (both determined fluospectrophotometrically and spectrophotometrically in general).

The effective amount of the 5-ASA or ester or salt thereof contained in the enema depends upon the extent of the disease and for adults generally in amounts of from 0.2 to 4 g 5-ASA per 100 ml enema will be used. Whether or not the enema- is a suspension or solution i.a. depends on the amount of 5-ASA and the pH. The solubility of 5-ASA in water is about 2 g/100 ml at pH 7, but only about 0.2 g/100 ml at pH 4.8.

By administering an enema suspension, which might be provided at the more acidic pH values in the range from 4 to 7, a kind of slow-release of the 5-ASA might be obtained.

Since 5-ASA is assumed to be topically effective at the ulcer sites in case of colitis such slow release is believed to be the most beneficial to the patient.

The enema solution or suspension also contains a chelating agent to avoid autooxidation catalyzed by metal ions which may be present even in analytic grade chemicals. Any of the classic chelating agents may be used, but the preferred chelating agents are polymethylene diaminetetraacetic acid, in particular, ethylene diaminetetraacetic acid (EDTA) and its alkali metal salts. The preferred amount of chelating agent is from 5 to 30 mg/100 ml solution or suspension, preferably about 20 mg/100 ml.

Further, the solution or suspension contains an antioxidant to prevent oxidation of the 5-ASA. Preferred antioxidants are sodium or potassium pyrosulfite, but other well-known antioxidants might be used, e.g., ascorbic acid. The preferred amount is 50-200 mg/100 ml suspension or solution, preferably about 100 mg/100 ml.

Further, the enema solution contains a suitable buffer in order to maintain the desired pH value in the range of from 4 to 7. The preferred pH is from 4.5 to 5, in particular, about 4.8. This pH is advantageously established by means of a citric acid buffer since citric, acid has a pka of 4.77.

Other applicable buffers are bicarbonate buffers if a pH of 6 to 7 is desired since the pka for bicarbonate is 6.5.

Generally speaking, any buffer system might be used which provides the proper pH and does not interfere with the other components of enema.

The gas used in the bottle and the package should be inert with relation to the solution or suspension. Preferred inert gases are nitrogen or argon, but also carbon dioxide may be used if the solution or suspension contains a bicarbonate buffer.

The plastic bottle is preferably made by blow forming from a polyethylene granulate which has been deoxidized by alternating vacuum and nitrogen treatments.

The diffusion-tight light-impervious package material is preferably made from a heat-sealable plastic-metal laminate, e.g., plastic-aluminum laminate, where any heat-sealable plastic material, e.g., polyethylene, might be used.

DESCRIPTION OF THE PREFERRED EMBODIMENT

A packaged suspension according to the invention may be prepared as follows:

1. Preparation of a 5-ASA suspension

______________________________________5-ASA*         1 g/100 mlEDTA           20 mgSodium pyrosulfite          0.2 gCitric acid    1 gSodium hydroxide          q.s. (up to pH = 4.8 about 0.35 g)Sterile water  up to 100 ml______________________________________ *5-ASA is extremely pure to avoid autooxidiation  no additional HPLC peak (both fluospectrophotometrically and spectrophometrically in general).

The suspension is prepared and dispensed in an inert gas, e.g., nitrogen or argon.

2. Filling of 5-ASA suspension in a plastic bottle

The polyethylene granulate is deoxidized by alternating vacuum and nitrogen treatments. The deoxidized granulate is extruded, formed by blowing and the 5-ASA suspension is filled into a plastic bottle blower/packing machine. The inert gas used for dispensing also constitutes the supporting air, blowing air and the air in the chamber in which the filling and forming procedures are taking place.

The bottle is conveyed directly to a packing chamber containing the same inert gas in which the bottles are packed in aroma-tight, light-impervious (plastics aluminum laminate) bags which are sealed by welding before they drop into the atmosphere.

Enema suspensions contain 1 g and 2 g 5-ASA per 100 ml prepared in analogy with the above procedure have been tested for stability by fluospectrophotometry and HPLC.

After storage at room temperature for more than a year, no significant change was observed neither with regard to color or 5-ASA content.

It is also to be understood that the following claims are intended to cover all of the generic and specific features of the invention herein described, and all statements of the scope of the invention which, as a matter of language, might be said to fall therebetween.

Patent Citations
Cited PatentFiling datePublication dateApplicantTitle
US2647853 *Nov 28, 1950Aug 4, 1953Lab Francais ChimiotherapieInjectable solution of salt of para-aminosalicylic acid
US2658073 *Mar 18, 1950Nov 3, 1953Monsanto ChemicalsPurification of para-aminosalicylic acid and its alkali metal salts
US2844625 *Sep 13, 1954Jul 22, 1958Miles Labp-aminosalicylic acid
US2939818 *Apr 9, 1957Jun 7, 1960Pfizer & Co CAqueous therapeutic compositions
US3044118 *Jun 23, 1958Jul 17, 1962Du PontMolding method and apparatus
US3230143 *May 14, 1965Jan 18, 1966Merck & Co IncAntihypertensive injection methods using acid addition salts of alkyl esters of alpha-methyl-3, 4-dihy-droxyphenylalanine
US3621892 *Sep 4, 1969Nov 23, 1971Gillespie Thomas JResin vacuum degassing and dispensing system and method
US3777019 *Feb 3, 1971Dec 4, 1973American Home ProdStabilized chlorpromazine hydrochlo-ride solution for use in disposable cartridges
US3937778 *Oct 24, 1974Feb 10, 1976Toshiba Kikai Kabushiki KaishaMethod of vacuum-pressure injection moulding
US4071620 *Jan 10, 1977Jan 31, 1978American Home Products CorporationStabilization of oxygen sensitive dose forms
US4150744 *Nov 23, 1977Apr 24, 1979Smith & Nephew Pharmaceuticals Ltd.Packaging
US4340550 *Nov 24, 1980Jul 20, 1982E. I. Du Pont De Nemours And CompanyOligomer pellets of ethylene terephthalate
US4406888 *Jan 9, 1981Sep 27, 1983Pfizer Inc.Aqueous micellar solutions of levonantradol and N-methyllevonantradol and lyophilic forms thereof for reconstitution
US4440763 *Mar 18, 1981Apr 3, 1984Block Drug Company, Inc.Use of 4-aminosalicyclic acid as an anti-inflammatory agent
US4447373 *Feb 16, 1982May 8, 1984The Procter & Gamble CompanyProcess for making filled articles from polymeric material
US4657900 *Mar 28, 1985Apr 14, 1987Rowell LaboratoriesPharmaceutical article of manufacture comprising a bisulfite stabilized aqueous solution of 5-aminosalicylic acid and method
DD150694A1 * Title not available
DE2712934A1 *Mar 24, 1977Oct 5, 1978Mundipharma AgMittel, insbesondere gegen hautschaeden durch ultraviolette strahlung, sowie verfahren zu seiner herstellung
DK120280B Title not available
WO1981002671A1 *Mar 20, 1981Oct 1, 1981Ferring Farma LabPharmaceutical composition and method for the treatment of colitis ulcerosa and crohn's disease by oral administration
WO1981002672A1 *Mar 20, 1981Oct 1, 1981Ferring Farma LabPharmaceutical composition and method for the treatment of colitis ulcerosa and crohn's disease
Non-Patent Citations
Reference
1Allgayer, H. et al., "Determination of the pK Values of 5-Aminosalicyclic Acid and N-Acetylaminosalicylic Acid and Comparison of the pH Dependent Lipuid-Water Partition Coefficients of Sulphasalazine and its Metabolites", Arzneim, Forsch. 35(II), No. 9 (1985), pp. 1457-1459.
2 *Allgayer, H. et al., Determination of the pK Values of 5 Aminosalicyclic Acid and N Acetylaminosalicylic Acid and Comparison of the pH Dependent Lipuid Water Partition Coefficients of Sulphasalazine and its Metabolites , Arzneim, Forsch. 35(II), No. 9 (1985), pp. 1457 1459.
3 *Angren, A., J. Pharm. Pharmac, vol. 7, p. 549.
4Binder, V. et al., "Topical 5-Aminosalicyclic Acid Versus Prednisolone in Ulcerative Proctosigmoiditis", Digestive Diseases & Sciences, Oct. 3, 1985.
5 *Binder, V. et al., Topical 5 Aminosalicyclic Acid Versus Prednisolone in Ulcerative Proctosigmoiditis , Digestive Diseases & Sciences, Oct. 3, 1985.
6Bondesen, S. et al., "5-Aminosalicyclic Acid Enemas in Patients with Active Ulcerative Colitis", Scand. J. Gasterenterol 19:677-687 (1984).
7 *Bondesen, S. et al., 5 Aminosalicyclic Acid Enemas in Patients with Active Ulcerative Colitis , Scand. J. Gasterenterol 19:677 687 (1984).
8Campieri, M. et al., "Treatment of Ulcerative Colitis with High-Dose 5-Aminosalicyclic Acid Enemas", LANCET, Aug. 8, 1981, pp. 270-271.
9 *Campieri, M. et al., Treatment of Ulcerative Colitis with High Dose 5 Aminosalicyclic Acid Enemas , LANCET, Aug. 8, 1981, pp. 270 271.
10Hvidberg, S. et al., "The Fate of 5-Amino-Salicyclic After Rectal Instillation in Patients with Active Procto-Sigmoiditis", CPT 83 Abstract.
11 *Hvidberg, S. et al., The Fate of 5 Amino Salicyclic After Rectal Instillation in Patients with Active Procto Sigmoiditis , CPT 83 Abstract.
12Khan, A. K. et al., "An Experiment to Determine the Active Therapeutic Moiety of Sulphasalazine", LANCET, Oct. 29, 1977, pp. 892-895.
13 *Khan, A. K. et al., An Experiment to Determine the Active Therapeutic Moiety of Sulphasalazine , LANCET, Oct. 29, 1977, pp. 892 895.
14 *Martindale, the Extra Pharmacopoeia, 28th Edition, the Pharmaceutical Press, 1982, 6673 e, Sodium Metabisulphite, pp. 1291 1292.
15Martindale, the Extra Pharmacopoeia, 28th Edition, the Pharmaceutical Press, 1982, 6673-e, Sodium Metabisulphite, pp. 1291-1292.
16Rhodes, J. M., "Medical Treatment of Ulcerative Colitis and Crohn's Disease", Journal of Clinical and Hospital Pharmacy (1983, 8, 219-232).
17 *Rhodes, J. M., Medical Treatment of Ulcerative Colitis and Crohn s Disease , Journal of Clinical and Hospital Pharmacy (1983, 8, 219 232).
18Willoughby, C. et al, "5-Aminosalicyclic Acid (Pentasa) in Enema Form for the Treatment of Active Ulcerative Colitis", Ital. J. Gastoenterol., 1986; 18: 15-17.
19 *Willoughby, C. et al, 5 Aminosalicyclic Acid (Pentasa) in Enema Form for the Treatment of Active Ulcerative Colitis , Ital. J. Gastoenterol., 1986; 18: 15 17.
Referenced by
Citing PatentFiling datePublication dateApplicantTitle
US5668123 *Aug 30, 1996Sep 16, 1997SynthelaboMethod of maintaining remission from venous ulcers with sulphasalazine and its metabolite
US5716648 *Jun 8, 1994Feb 10, 1998Farmaceutisk Laboratorium Ferring A/SCompositions for use in the regulation of subnormal pH values in the intestinal tract and for treatment of bowel diseases
US6326364Feb 8, 1999Dec 4, 2001Cedars-Sinai Medical CenterUse of 5-aminosalicylates as antimicrobial agents
US6583128Aug 29, 2001Jun 24, 2003Nobex CorporationImmunoregulatory compounds and derivatives and methods of treating diseases therewith
US6903082May 23, 2003Jun 7, 2005Nobex CorporationMethods of treating inflammatory conditions of the gastrointestinal tract using 4-APAA and compositions thereof
US7425578Sep 7, 2006Sep 16, 2008Biocon LimitedImmunoregulatory compounds and derivatives and methods of treating diseases therewith
US7645801May 16, 2007Jan 12, 2010Alaven Pharmaceutical LlcReduced irritant enema for treatment of inflammatory bowel disease (IBD)
US7932366Jul 7, 2005Apr 26, 2011Biocon LimitedSynthesis of azo bonded immunoregulatory compounds
US8048924Mar 22, 2005Nov 1, 2011Biocon LimitedMethods and compositions employing 4-aminophenylacetic acid compounds
US8147445Jun 14, 2005Apr 3, 2012C.B. Fleet Company Inc.Enema dispenser
US8217082Dec 10, 2009Jul 10, 2012Alaven Pharmaceutical, LlcReduced irritant enema for the treatment of inflammatory bowel disease (IBD)
US8314214Apr 26, 2011Nov 20, 2012Biocon LimitedSynthesis of azo bonded immunoregulatory compounds
US8754197Nov 19, 2012Jun 17, 2014Biocon LimitedSynthesis of azo bonded immunoregulatory compounds
US8845577Mar 2, 2012Sep 30, 2014C.B. Fleet Company, Inc.Enema dispenser
US9533129Jul 22, 2014Jan 3, 2017C.B. Fleet Company, Inc.Enema dispenser
US20050255170 *May 13, 2004Nov 17, 2005Post Sarah SLarge volume enema
US20070004800 *Sep 7, 2006Jan 4, 2007Biocon LimitedImmunoregulatory compounds and derivatives and methods of treating diseases therewith
US20070005025 *Jun 14, 2005Jan 4, 2007Cox Charles HEnema dispenser
US20100087537 *Dec 10, 2009Apr 8, 2010Alaven Pharmaceutical LlcReduced irritant enema for the treatment of inflammatory bowel disease (ibd)
US20110066117 *Nov 23, 2010Mar 17, 2011Post Sarah SLarge volume enema
Classifications
U.S. Classification206/213.1, 514/166
International ClassificationB65D81/20, A61K9/00, A61K31/60
Cooperative ClassificationA61K9/0031, B65D81/2092, A61K31/60, B65D2565/387, Y02W30/806
European ClassificationB65D81/20F2A, A61K31/60, A61K9/00M6
Legal Events
DateCodeEventDescription
Sep 23, 1994FPAYFee payment
Year of fee payment: 8
Nov 12, 1998FPAYFee payment
Year of fee payment: 12